Protectimmun Raises €1.7M

Protectimmun GmbH, a Gelsenkirchen, Germany-based biopharmaceutical company focused on research and development of drugs especially in the field of allergic and chronic inflammatory diseases, has closed a €1.3m first financing round.

Investors include High-Tech Gründerfonds (HTGF), ELS-Fonds managed by EnjoyVenture, KfW, a private investor and the team of founders.

As stated by CEO and co-founder Dr. Marion Kauth, Protectimmun intends to use the funds to proceed with pre-clinical testing and prepare for clinical studies.

Based on research by Ruhr-University Bochum and Research Centre Borstel, the company is developing a pharmaceutical composition that may offer long-lasting protection against the development of allergic airway diseases to children.



Join the discussion